[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-vasculitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-vasculitis":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100254637","vasculitis-pregnancy-registry-100254637",false,"NCT02593565","Vasculitis Pregnancy Registry","The Vasculitis Pregnancy Registry (V-PREG)","V-PREG","Inclusion Criteria:\n\n1. Women 18 years of age or older with one of the following diseases may take part in the study:\n\n   * Behçet's disease;\n   * Central nervous system (CNS) vasculitis;\n   * Cryoglobulinemic vasculitis (Cryoglobulinemia);\n   * Eosinophilic granulomatosis with polyangiitis (also called Churg-Strauss Syndrome);\n   * Giant Cell (Temporal) Arteritis (GCA);\n   * Granulomatosis with polyangiitis (also called Wegener's);\n   * IgA vasculitis (Henoch-Schoenlein purpura);\n   * Microscopic polyangiitis (MPA);\n   * Polyarteritis nodosa (PAN);\n   * Takayasu's arteritis (TAK);\n   * Urticarial vasculitis;\n   * Other\u002FSuspected Diagnosis.\n2. Women must be pregnant (self-report) at the time of enrollment into the registry.\n\nExclusion Criteria:\n\n1. Non-English speaking, with the exception of people who speak Spanish, Portuguese, Italian, or Turkish.\n2. Unable to provide consent.","FEMALE","18 Years","50 Years",{"count":21,"type":22},100,"ESTIMATED","12 Months","OBSERVATIONAL","The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several online surveys to assess\n\n1. each woman's vasculitis severity and pregnancy-related experiences, and\n2. pregnancy outcomes.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Vasculitis","Behcet's Disease","CNS Vasculitis","Cryoglobulinemic Vasculitis","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Churg-Strauss Syndrome (CSS)","Granulomatosis With Polyangiitis (GPA)","Wegener's Granulomatosis","IgA Vasculitis","Henoch-Schoenlein Purpura (HSP)","Microscopic Polyangiitis (MPA)","Polyarteritis Nodosa (PAN)","Takayasu Arteritis (TAK)","Urticarial Vasculitis","Systemic Vasculitis","RECRUITING","2026-01-21",{"date":45,"type":46},"2026-01-23","ACTUAL",{"date":48,"type":4},"2015-11",{"date":50,"type":22},"2027-12",{"name":52,"class":53},"University of Pennsylvania","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":54},"100595844","circulating-b-cell-drug-and-anti-drug-antibodies-monitoring-in-patients-treated-with-rituximab-for-autoimmune-disorders-100595844","NCT07037732","Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders","Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders : the MONIRITUX Study","Inclusion Criteria:\n\n* Patient who undergo rituximab treatment according to routine care and having one of the following disorder:\n* primary immune thrombocytopenia\n* primary autoimmune hemolytic anemia\n* systmic lupus erythematous\n* systemic sclerosis\n* rheumatoid arthritis\n* inflammatory myopathy\n* ANCA associated vasculitis\n* Cryoglobulinemic vasculitis\n\nExclusion Criteria:\n\n* Patients undergoing multiple immunosuppressive drugs because of refractory disease or concomitant hemopathy or malignancy","ALL",{"count":64,"type":22},50,"The MONIRITUX study aimed to evaluate whether monitoring (i) circulating B-cell reconstitution or (ii) serum rituximab levels could help identify relapse of autoimmune diseases in patients treated with rituximab. Retrospective data suggest that B-cell reconstitution or the appearance of anti-drug antibodies are associated with rituximab's failure to prevent relapses (i.e. rheumatoid arthritis, systemic lupus erythematosus, autoimmune cytopenia...). According to the routine care provided by our institution, patients undergoing rituximab therapy are monitored every three months during the first year after treatment induction and every six months thereafter. At each clinical visit, a blood test is performed to quantify total gammaglobulins, IgG and CD19+ cells (along with other tests depending on the disease). This study will use the remaining blood in the tubes from routine care to quantify CD27+ and CD38+ B cells, as well as serum rituximab and anti-rituximab antibodies, during the first year of follow-up. The primary outcome will be to identify risk factors for clinical relapse according to circulating B-cell or rituximab status.",[67,68,41],"Autoimmune Cytopenia","Connective Tissue Disorder","2025-06-23",{"date":71,"type":46},"2025-06-25",{"date":73,"type":46},"2025-06-01",{"date":75,"type":22},"2030-06-01",{"name":77,"class":53},"Centre Hospitalier Universitaire de Nice",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":62,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":88,"conditions":89,"keywords":95,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":54},"100565491","rare-autoimmune-self-management-programme-development-100565491","NCT06642870","Rare AutoImmune SElf-management Programme Development","Rare Autoimmune Self-management Programme Development","RAISE","Inclusion Criteria:\n\n1. Diagnosis of a rare rheumatic condition made by hospital doctor or secondary care: including lupus, systemic vasculitis, myositis, Sjogren syndrome (participant self-report)\n2. Ability to give informed consent (with translation support if needed)\n\nExclusion Criteria:\n\n\\-",{"count":87,"type":22},360,"The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic diseases such as heart failure. The aim of the study is to explore content and structure of a support programme for people with RAIRDs in focus groups and survey meetings.",[90,41,91,92,93,94],"Systemic Lupus Erthematosus","Inflammatory Myositis","Systemic Sclerosis (SSc)","ANCA Associated Vasculitis (AAV)","Sjogren Syndrome",[96,97,98],"Rare autoimmune rheumatic diseases","Self-management","Psychological support","2024-10-14",{"date":101,"type":46},"2024-10-15",{"date":103,"type":22},"2024-10",{"date":105,"type":22},"2026-04",{"name":107,"class":53},"University of the West of England"]